SEC Filing Summary: Bioptix, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioptix, Inc. on September 25, 2017, covering events occurring on September 19 and September 20, 2017. The filing addresses a change in the company's state of incorporation and a significant capital structure transaction involving the exchange of debt for equity.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial activity disclosed is the "Exchange Transaction" on September 20, 2017:
- Debt Converted: $4,798,671 of outstanding convertible promissory notes.
- Equity Issued: 19,194.72 shares of 2% Series A Convertible Preferred Stock.
- Conversion Rights: The preferred shares are convertible into an aggregate of 1,919,472 shares of Common Stock.
- Preferred Stock Authorization: 2,000,000 shares of 2% Series A Convertible Preferred Stock were designated.
Material Changes Versus Prior Period
The filing details two material corporate changes:
- Reincorporation: Effective September 19, 2017, the company changed its state of incorporation from Colorado to Nevada. Stockholder rights are now governed by Nevada corporation laws, Articles of Incorporation, and By-Laws.
- Debt-to-Equity Exchange: The company executed an exchange of approximately $4.8 million in notes for preferred stock, reducing outstanding debt obligations and increasing equity capitalization.
Guidance, Risks, and Unusual Items
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the structural changes noted. The Exchange Transaction was executed in reliance on the exemption from registration requirements under Section 3(a)(9) of the Securities Act. The filing references a Proxy Statement filed on July 7, 2017, for a detailed description of changes to stockholder rights resulting from the reincorporation.
Investor Verification Checklist
- Verify the terms of the 2% Series A Convertible Preferred Stock (dividend rights, liquidation preferences, and conversion mechanics) in the filed Certificate of Designation (Exhibit 3.3).
- Review the Proxy Statement filed July 7, 2017 to understand specific changes to stockholder rights under Nevada law compared to the previous Colorado jurisdiction.
- Confirm the remaining balance of the original $4,750,000 convertible promissory note facility, as $4,798,671 was exchanged (suggesting the full facility plus potential interest was converted).
- Check for any subsequent filings regarding the conversion of the 1,919,472 shares of Common Stock underlying the preferred stock.